NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume – What’s Next?

Shares of NewAmsterdam Pharma (NASDAQ:NAMS) saw an uptick in trading volume on Monday . 501,403 shares were traded during trading, an increase of 85% from the previous session’s volume of 271,041 shares.The stock last traded at $25.23 and had previously closed at $24.90.

Analyst Ratings Changes

A number of brokerages recently weighed in on NAMS. Royal Bank of Canada restated an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Piper Sandler reissued an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, November 7th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $33.80.

NewAmsterdam Pharma Stock Down 1.0 %

The company’s 50 day moving average price is $18.52 and its two-hundred day moving average price is $18.58.

Insider Buying and Selling

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 45,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total value of $707,400.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 19.50% of the stock is currently owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

A number of large investors have recently made changes to their positions in NAMS. StemPoint Capital LP purchased a new position in NewAmsterdam Pharma in the 1st quarter worth about $1,900,000. Affinity Asset Advisors LLC increased its position in shares of NewAmsterdam Pharma by 129.0% during the first quarter. Affinity Asset Advisors LLC now owns 286,200 shares of the company’s stock worth $6,769,000 after acquiring an additional 161,200 shares during the period. Baker BROS. Advisors LP bought a new stake in shares of NewAmsterdam Pharma during the first quarter valued at approximately $2,290,000. Janus Henderson Group PLC purchased a new stake in shares of NewAmsterdam Pharma in the first quarter valued at approximately $15,018,000. Finally, Artal Group S.A. bought a new position in NewAmsterdam Pharma in the first quarter worth approximately $18,920,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.